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1. Introduction 
An immunosuppression [IS]-free state is the ultimate goal to achieve in solid organ 
transplantation [SOT] because IS-related toxicity tremendously impact on overall clinical 
outcome [Orlando, Hematti et al., 2010]. The IS-free state substantiates into what is referred 
to as clinical operational tolerance [COT], defined as the condition in which a SOT recipient 
retains stable graft function and lacks histological signs of rejection, after having been 
completely off all IS for at least 1 year. The patient in question is an immunocompetent host 
capable of responding to other immune challenges, including infections or transplantation 
of organs from third party donors [Orlando, Hematti et al., 2010; Orlando et al., 2008]. 
However, experimental and clinical information collected so far show that COT is extremely 
difficult to achieve and is organ-dependent. In fact, the majority of cases of COT reported so 
far relate to liver graft recipients, in reason of the well known immune-privileged status of 
the liver determined by factors that remain obscure. 
In this chapter, we will provide evidence that the achievement of COT after RT remains 
exceptional and that tolerogenic strategies are not yet available for daily clinical practice. To 
do so, we will illustrate and discuss the most relevant cases of COT described so far in the 
English literature. However, by briefly touching the recent outstanding progress achieved in 
regenerative medicine, we will bring the attention of the reader on the fact that regenerative 
medicine may offer a valuable approach to generate immediate, stable and durable COT in 
SOT recipients. 
2. Classification 
Several classifications have been proposed to categorize all strategies proposed so far to 
induce COT in RT recipients [Fehr & Sykes, 2004; Orlando et al, 2008; Orlando, Hematti et 
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al, 2010]. Nevertheless, given the interest and enthusiasm generated by recent investigations 
in the field of stem cell biology, we believe that so-called tolerogenic strategies –  namely, 
protocols implemented to induce COT – may be divided into two new groups, cell-based 
and non-cell-based, according to whether or not stem cell strains showing some 
immunomodulatory effect in vitro are administered in the preoperative period in addition to 
standard IS.  
2.1 Cell-based approach 
2.1.1 Metachronous bone-marrow transplant for hematologic disorders 
Bone marrow transplantation [BMT], results in the total replacement of the recipient’s bone 
marrow by the donor’s bone marrow hematopoietic cells, a condition referred to as full 
chimerism [Delis et al, 2004]. If the patient receives an organ from the same bone marrow 
donor late after BMT, then the reconstituted white cell compartment may recognize the new 
organ as self; theoretically, no response will be mounted by the host immune system and the 
new graft will be tolerated without need for any IS. However, despite several cases of BMT 
plus solid organ transplants [RT included] have been reported [Butcher et al, 1999; Chiang & 
Lazarus, 2003; Helg et al, 1994; Jacobsen et al, 1994; Light et al, 2002; Sayegh et al, 1991; 
Sellers et al, 2001; Sorof et al, 1995], yet COT has been an exceptional finding. Importantly, 
according to what reported by all series, COT developed in patients in which the transplant 
was performed several years after BMT, but never where BMT and RT were performed 
simultaneously.  
2.1.2 Perioperative infusion of HSC 
Somehow, the above reported data conflicted with what described in mice by Monaco and 
Wood, namely that the addition of donor bone marrow to a strong lymphocyte depleting 
regimen may result in the long-lasting survival of skin allografts from the same donor, 
without any maintenance IS [Monaco et al, 1970; Monaco et al, 1976; Monaco et al, 1985]. 
These experimental findings represented the platform for translational investigations aimed 
to prove that the peroperative infusion of donor-derived bone marrow cells can prolong 
allograft survival [Sykes, 2009]. The group at Massachusetts General Hospital adopted such 
strategy in 7 adult patients with renal failure due to multiple myeloma, who received 
combined human leukocyte antigen [HLA]-matched kidney and bone marrow transplant 
after a non-myeloablative conditioning regimen consisting of cyclophosphamide, 
antithymocyte globulin, and pretransplant thymic irradiation [Buhler et al, 2002; Fudaba et 
al, 2006; Spitzer et al, 1999; Spitzer et al, 2011]. Maintenance IS consisted of cyclosporine 
which was discontinued as early as day 73 post-transplant.  Patients were followed for a 
mean of 7.4 (range 4-12) years. Two of them died for relapse of the baseline disease and 
therapy-related acute myeloid leukemia after 7.7 and 4.2 years, respectively; noteworthy, 
both were IS-free at the time of death. Of the 5 patients who are still alive [4 of whom with 
no evidence of myeloma recurrence], 3 are IS-free, and show serum creatinine levels of 0.63, 
1.14 and 1.7 mg/dL, respectively. The remaining 2 individuals are receiving either 
prednisone or tacrolimus for graft-versus-host disease [but no rejection!], and present serum 
creatinine levels of 0.9 and 1.42 mg/dL. 
More recently, the same group reported the short-term results of a seminal trial in which 
non-cancer patients received renal grafts and bone marrow from HLA haploidentical donors 
following nonmyeloablative conditioning to induce renal allograft tolerance [Kawai et al, 
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2008; Porcheray et al, 2009]. Even in this case, cyclosporine was the only 
immunosuppressant used for maintenance therapy. IS could be successfully weaned in 4 out 
of 5 patients, whereas the remaining patient experienced acute rejection and lost his graft. 
Cyclosporine could be withdrawn after 294 (range 240-272) days. However, matters of 
concern are represented by two major findings. First, the reported most recent mean 
creatinine clearance (67 ml/min, range 60-75) and serum creatinine levels (1.5 mg/dl, range 
1.2-1.8) levels in the 4 IS-free patients were slightly abnormal. Second, 2 of these patients 
have shown evidence of de novo antibodies reactive to donor antigens between 1 and 2 years 
after the transplant [Porcheray et al, 2009]. Overall, this series demonstrates that B-cell 
immunity can occur in the context of T-cell tolerance to donor antigens through unknown 
mechanisms, otherwise said T-cell unresponsiveness is not synonymous of tolerance of both 
arms of the adaptive immune system. This is consistent with information reported by 
Nantes. Soulillou et al. extensively studied IS-free RT recipients [Ashton-Chess et al., 2007; 
Baeten et al., 2006; Ballet et al., 2006; Brouard et al., 2005; Louis et al., 2006; Roussey-Kesler et 
al., 2006;] and found that COT may occur in the presence of anti-donor class II antibodies, as 
well as in patients who have previously experienced acute rejection. Moreover, they showed 
that IS-free RT recipients are more likely to have received grafts from donors younger than 
30 years of age, are low-responders to blood transfusion, may develop graft dysfunction at 
any time after the weaning of IS, and show an incidence of infectious diseases comparable to 
that in normal individuals. 
The Stanford group has implemented a similar strategy in two distinct small series, where 
patients received a renal graft followed by the infusion of HSC from the same HLA-
mismatched (x4) or -matched (x6) donors, respectively [Millan et al., 2002; Scandling et al., 
2008]. IS consisted of induction with total lymphoid irradiation and rabbit anti-thymocyte 
globulin, followed by cyclosporine and prednisone as maintenance therapy. After steroid 
discontinuation on day 10, mycophenolate mofetil was introduced and administered for 1 
month. Intravenous injection of HSC was repeated during the third postoperative week. 
Results were poor. In the first trial, only one patient could be weaned off IS, while 
however showing slightly elevated serum creatinine leves (1.4 mg/dL). In the second 
trial, one individual could be weaned off IS but renal function tests are not shown. Two 
further patients rejected, while the remaining 3 were still under weaning at the time of 
publication. 
Overall, based on the reported information, the above series show the lack of safety of 
hematopoietic stem cell-based regimens. Despite this approach may allow minimization 
of overall IS, however further studies are required to improve safety and effectiveness. 
Importantly, most of the IS-free patients reported above do not comply with the stringent 
criteria for COT adopted in the present chapter.   
2.1.3 Perioperative infusion of alternative types of immunomodulatory cells 
Transplant-acceptance-inducing cells (TAIC) are immunoregulatory macrophages which 
have shown some capacity of establishing a state of alloantigen-specific partial tolerance of 
solid organ transplants in renal transplant recipients [Hutchinson, Brem-Exner et al., 2008; 
Hutchinson, Riquelme et al., 2008; Riquelme P et al., 2009]. TAIC’s presumed tolerogenic 
properties have been tested in two safety trials differing in the method for TAIC 
preparation, numbers of cells infused, induction IS, and timing of infusions. None of the 17 
patients enrolled in either study could be weaned off IS, most of them rejected, 2 dropped 
out the study for non-immunological causes, while only 2 individuals did well yet under 
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tacrolimus monotherapy at the end of the study. Overall, although these trials demonstrated 
that the infusion of TAIC is feasible, major concerns remain regarding the efficacy and safety 
of such an approach. It is unclear whether or not this approach confers any benefit in the 
establishment of minimal IS in RT patients when compared to the protocols currently 
adopted, as clearly stated by authors in the discussion. Lastly, the optimal dose and timing 
of cell infusions, as well as the most appropriate concomitant IS regimen, is yet to be 
determined. 
For their ability for tissue repair and immunomodulation, mesenchymal stem cells (MSCs) 
are currently being evaluated for a wide variety of clinical applications including the 
treatment of disorders characterized by a dysfunction of immune regulation, such as graft 
versus host disease after bone marrow transplantation and rejection after cell or organ 
transplantation [Crop et al., 2009; Ding et al., 2009; Hematti, 2008; Le Blanc et al., 2008; Le 
Blanc & Ringden, 2007]. As MSCs seem to be able to promote engraftment of allogeneic 
cells, tissues and organs, as well as to prevent or treat rejection in pre-clinical models, they 
provide an exciting opportunity for further research in the field of IS minimization and 
withdrawal in SOT [Hematti, 2008; Hoogduijn MJ et al., 2010]. 
It is worth to mention that, in addition to stem cells, the therapeutic properties of various 
other immune cells like regulatory T cells or dendritic cells are currently being explored for 
SOT purposes [Issa, Hester et al., 2010; Issa, Schiopu et al., 2010; Orlando, Hematti et al., 
2010]. 
2.2 Non cell-based protocols 
2.2.1 Non-adherence to IS 
The majority of cases of COT described so far after RT is represented by patients who 
spontaneously decided to stop IS for non-compliance to treatment [Ashton-Chess et al., 
2007; Baeten et al., 2006; Ballet et al., 2006; Brouard et al., 2005; Hussey, 1975; Louis et al., 
2006; Najarian, 1975; Newell et al., 2010; Owens et al., 1975; Roussey-Kesler et al., 2006; 
Sagoo et al., 2010; Uehling et al., 1976; Zoller et al., 1980]. These patients have been the object 
of numerous investigations conducted at different times by diverse authors with methods 
presenting dissimilar accuracy. However, we believe that it is worth to report the 
investigations by Burlingham et al. In an attempt to identify patients who may be weaned 
off IS at no risk, he recurred to the human-to-mouse trans-vivo delayed-type 
hypersensitivity assay [Geissler et al., 2001; VanBuskirk et al., 2000]. By observing that 2 
renal allograft recipients failed to exhibit donor-reactive delayed type hypersensitivity 
responses, although they frequently develop donor-reactive alloantibodies, the authors 
demonstrated that this pattern of immune responses is not due to an absence of 
allosensitization, but to the development of an immune mechanism that actively inhibits 
anti-donor delayed-type (i.e., cell-mediated) immune responses. In other words, authors 
provided evidence that COT develops following the onset of regulatory, rather than 
suppressing  mechanisms. 
Of interest is the case of spontaneous interruption of IS by a 24-year old woman who had 
received a deceased donor RT at the age of 13 for membranoproliferative 
glomerulonephritis. When the woman found out to be pregnant, she stopped all IS to 
protect the fetus from any possible IS-induced teratogenic effect [Fischer et al., 1996]. 
Interestingly, she did not resume any IS after delivery, and no immunological response was 
observed for 9 years after the withdrawal of IS, while the patient was showing perfectly 
normal renal function tests. 
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2.2.2 Molecule-based tolerogenic protocols 
A molecule-based tolerogenic regimen was implemented by Starzl a decade ago [Starzl et 
al., 2003]. The working hypothesis was that the need for continual high dose IS could be 
avoided in most cases with the use of a strong lymphocyte-depleting regimen prior to 
engraftment, followed by the administration of low dose tacrolimus monotherapy. The 
rationale was to remove the non-specific clones of immune cells responsible for rejection 
before contact with foreign donor antigens occurs. Once the donor antigens are in place after 
implantation of the new organ, repletion of immune cells occurs, favored by the homeostatic 
expansion triggered by leukocyte depletion. In addition, minimization of maintenance IS 
was implemented to further reduce the anti-donor response with just enough treatment to 
prevent irreversible immune damage to the graft, but not with such heavy treatment that 
the donor-specific clonal exhaustion-deletion process is precluded. 
Broadly reacting rabbit antithymocyte globulins were administered preoperatively, 
followed by tacrolimus monotherapy, to 82 adult kidney, liver, pancreas, and intestinal 
transplant recipients. After a mean follow-up time of 18-months, 1-year patient and graft 
survival rates were 95% and 82% overall, respectively, IS-related morbidity was virtually 
eliminated, and 48/72 surviving patients were receiving spaced doses of tacrolimus 
monotherapy. Noteworthy, 25/39 (64%) renal, 12/17 (70%) liver, 5/12 (42%) pancreas, as 
well as 6/11 (54%) intestinal transplant recipients, resulted on tacrolimus spaced doses at 
the time of publication. However, IS could not be weaned off in any patient. Other protocols 
based on a similar strategy – i.e., leukocyte depletion followed by the administration of low 
dose single-drug IS - have been implemented after RT [Agarwal et al., 2008; Calne et al., 
2000; Calne et al., 1999; Calne et al., 1998; Ciancio & Burke, 2008; Clatworthy et al., 2009; 
Kirk et al., 2003; Kirk et al., 2005; Orlando, Hematti et al., 2010; Trzonkowski et al., 2006; 
Trzonkowski et al., 2008; Watson et al., 2005] and liver, the organ most capable of 
developing COT, transplantation [Eason et al., 2005]. However, none of these protocols has 
proved effective or safe in producing COT nor has they shown any convincing impact on 
overall outcomes. 
2.2.3 Total lymphoid irradiation 
Three cases of COT have been described in RT recipients subjected to total lymphoid 
irradiation, a perioperative course of antithymocyte globulin, and maintenance prednisone 
that was gradually weaned and eventually stopped [Strober et al., 1989; Strober et al., 2000; 
Strober et al., 2004]. Two patients remained IS-free for 12 years and 69 months, while the 
third developed severe urinary tract obstruction 10 months after the IS withdrawal, for 
which he was eventually retransplanted. Importantly, the complete original series 
comprised 28 RT recipients, 25 of whom did not develop COT. 
2.2.4 COT developed after intentional IS withdrawal for lymphoproliferative disorders  
Two cases of COT developing after the intentional withdrawal of IS due to the development 
of post transplant lymphoproliferative disorders (PTLD) have been described, mainly 
within a larger series [Roussey-Kesler et al., 2006]. A third case relates to a 21-year-old man 
who received 2 haplo-identical RTs, the first at age 11 from his mother and the second at age 
15 from his father [Christensen et al., 1998]. Three years after the second RT, he developed 
PTLD. IS was promptly interrupted and the PTLD subsequently resolved. At the time of 
publication, IS had been withdrawn for 3 years with no rejection. 
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Classification Subtype Center Type of study Claimed cases 
of COT 
Length of 
follow up 
from the 
time of the 
withdrawal 
of the IS 
Cell-based Previous 
BMT 
Boston, Brigham 
and Women 
Hospital [Sayegh 
et al, 1991] 
Case report 2* 7 and 3 years 
Geneva [Helg et 
al, 1994] 
Case report 1 2 years 
Copenhagen 
[Jacobsen et al, 
1994] 
Case report 1 1 year 
San Francisco 
[Sorof et al, 1995] 
Case report 1 2 year 
Milwaukee 
[Bucther et al, 
1999] 
Case report 3 3, 11, 18 
years 
Birmingham, US 
[Sellers et al, 2001]
Case report 1 7 
HSC Boston, 
Massachussetts 
General Hospital 
[Spitzer et al, 
1999; Buhler et al, 
2002; Fudaba et al, 
2006; Spitzer et al, 
2011] 
Prospective, 
non 
comparative 
3/6 12.1, 7.7, 4, 
6.8 years 
Boston, 
Massachussetts 
General Hospital 
[Kawai et al, 2008; 
Porcheray et al, 
2009] 
Prospective, 
non 
comparative 
4/5 4.6, 3.4, 2.2 
and 1.2 years  
Stanford [Millan 
et al, 2002] 
Prospective, 
non 
comparative 
1/4 14 years 
Stanford 
[Scandling et al, 
2008] 
Prospective, 
non 
comparative 
1/3 28 months 
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Classification Subtype Center Type of study Claimed cases 
of COT 
Length of 
follow up 
from the 
time of the 
withdrawal 
of the IS 
Miami [Ciancio et 
al, 2004] 
Prospective, 
non 
randomized, 
comparative 
0/63 - 
TACI Kiel [Hutchinson 
et al, 2008] 
Prospective, 
non 
comparative 
0/12 - 
Kiel [Hutchinson 
et al, 2008] 
Prospective, 
non 
comparative 
0/5 - 
Non cell-
based 
Non-
adherence 
to IS 
Columbus-
Madison 
[VanBuskirk et al, 
2000; Geissler et 
al, 2001] 
Case report 3 3 years 
Madison [Uehling 
et al, 1976] 
Case report 5, but 4 rejected 
after few 
months 
5 years 
Los Angeles 
[Owens et al, 
1975] 
Case report 4, but eventually 
1 rejected after 
18 months 
17, 23, 52 
months 
Minneapolis 
[Najarian, 1975] 
Case report 6, but 5 rejected 
after few 
months 
NA 
Madison [Hussey, 
1975] 
Case report 8, but 7 rejected 
after few 
months 
40 
TBI Stanford [Strober 
et al, 1989; Strober 
et al, 2000] 
Prospective 3/28, but 1 
rejected after 10 
months for non-
immunological 
reasons 
144 and 69 
months 
Pregnancy Erlangen-Munster 
[Fischer et al, 
1996] 
Case report 1 9 years 
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Classification Subtype Center Type of study Claimed cases 
of COT 
Length of 
follow up 
from the 
time of the 
withdrawal 
of the IS 
PTLD Aarhus 
[Christensen et a, 
1998] 
Case report 1 >3 years 
Molecule-
based 
Pittsburgh [Starzl 
et al, 2003] 
Prospective, 
non 
comparative 
0/39 - 
Cambridge 
[Clatworthy et al, 
2009; Watson et 
al, 2005; Calne et 
al, 2000; Calne et 
al, 1999; Calne et 
al, 1998] 
Prospective, 
comparative, 
non 
randomized 
0/33 - 
Oxford 
[Trzonkoski et al, 
2008] 
Prospective, 
non 
comparative 
0/13 - 
Bethesda [Kirk et 
al, 2003] 
Prospective, 
non 
comparative  
0/7 - 
Bethesda [Kirk et 
al, 2005] 
Prospective, 
non 
comparative  
0/5 - 
Surveys Boston [Zoller et 
al, 1980] 
Descriptive, 
observational
13 >1 year 
Nantes [Roussey-
Kesler et al, 2006] 
Descriptive, 
investigative 
10, but 2 
rejected after 7 
and 13 years 
9 years 
[mean time, 
range 1-20] 
Nantes [Braud et 
al, 2008; 
Sivozhelezov et 
al, 2008] 
Descriptive, 
investigative 
8 >1 year 
Nantes [Bouard et 
al, 2007] 
Descriptive, 
investigative 
17 >1 year 
Los Angeles 
[Owens et al, 
1975] 
Descriptive, 
observational
24, but 22 
rejected after 
few months 
9, 36 months 
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Classification Subtype Center Type of study Claimed cases 
of COT 
Length of 
follow up 
from the 
time of the 
withdrawal 
of the IS 
European 
Consortium for 
tolerance  
[Sagoo et al, 2010]
Descriptive, 
investigative 
11 >1 year 
American 
network for 
immune tolerance 
[Newell et al, 
2010] 
Descriptive, 
investigative 
25 >1 year 
Table 1. Synoptic view of all successful and unsuccessful cases of COT described after RT. 
The mismatch between the number of cases claimed by numerous authors and the real 
effectice number of COT calculated according to the definition of COT adopted in the 
present manuscript is evident [116 vs. 108, respectively]. 
3. Immune monitoring 
As illustrated above, most cases of COT have developed in individuals who have 
spontaneously terminated IS. When all clinical trials in which a presumed tolerogenic 
protocol has been implemented are taken into consideration, it is frustrating to observe that 
COT could be obtained in only 6 out of 248 patients, accounting for a poor, unacceptable 
success rate of 2.5% [Orlando, Hematti et al , 2010]. As a corollary, the tolerogenic regimens 
attempted so far in RT recipients are not efficient and, more importantly, lack safety. Ideally, 
before implementing any of such regimens, investigators should rely on parameters able to 
predict with high accuracy whether patients would tolerate the weaning process without 
any risk to reject. Unfortunately, no parameter as such is available for routine practice, not 
even renal biopsy. For example, Burlingham reported on a late graft rejection in a patient 
who received a RT 9.5 years earlier from his mother and who had been IS-free for 7 years; a 
gradual rise in serum creatinine level to 2.0 mg/dl prompted a biopsy that ruled out 
rejection, yet 10 months later severe cellular rejection arose [Burlingham et al., 2000]. 
Investigators have obtained promising results in the field of liver transplantation where this 
problem has been circumvented by the identification of so-called markers of tolerance 
[Martinez-Llordella et al., 2008; Martinez-Llordella et al., 2007], defined as functional and 
molecular correlates of immune reactivity whose purpose is to provide clinically useful 
information for therapeutic decision-making in view of IS withdrawal [Ashton-Chess et al., 
2009]. Investigations in tolerant liver transplant recipients resulted in the discovery and 
validation of a tolerance-associated transcriptional patterns, consisting of several gene 
signatures and multiple peripheral blood lymphocyte subsets capable of identifying tolerant 
and non-tolerant recipients with high accuracy. As these data suggested that transcriptional 
profiling of peripheral blood can be employed to identify recipients who can discontinue 
immunosuppressive therapy at no risk for rejection, RT researchers are currently exploring a 
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signature of COT after RT which may allow the selection of those patients who may be more 
prone to develop an IS-free state with no or quasi no risk for rejection.   
The group in Nantes has pioneered investigations aimed to the identification of specific 
biological signatures of COT [Braud et al., 2008; Brouard et al., 2007; Sivozhelezov et al., 
2008]. Brouard et al. identified a set of 49 genes and differentially expressed gene transcripts 
using gene-expression profiling of peripheral blood from 17 tolerant RT recipients, with 
tolerance class prediction scores of >90% [Brouard et al., 2007]. This fingerprint is expected 
to identify patients who might be eligible for a progressive tapering of their 
immunosuppressive medications and, more importantly, those who instead need to stay on 
their current IS regimen. The same group has also exploited the capabilities of high 
throughput microarray technology to study peripheral blood specific gene expression 
profiles and corresponding molecular pathways associated with operational tolerance 
[Braud et al., 2008; Sivozhelezov et al., 2008]. Investigations revealed that tolerant patients 
display a set of 343 differentially expressed genes, mainly immune and defense genes, in 
their peripheral blood mononuclear cells (PBMC), of which 223 were also different from 
healthy volunteers. Using the expression pattern of these 343 genes, they were able to 
correctly classify >80% of the patients in a cross-validation analysis and correctly identified 
all of the samples over time. All together, this study identified a unique PBMC gene 
signature associated with human operational tolerance in kidney transplantation [Orlando, 
Hematti et al., 2010]. 
Investigations have been conducted in parallel in Europe and the United States.  The 
European Union Indices of Tolerance Network showed that IS-free RT patients present a 
distinctive expansion of peripheral blood B lymphocytes and natural killer cells and 
differential expression of several immune-relevant genes in the absence of donor-specific 
antibodies [Sagoo et al., 2010]. Similar population expansion of B immune cells and 
selective expression of B cell-related genes in samples obtained from tolerant individuals 
were noted by the National Institute of Health’s Immune Tolerance Network [Newell et 
al., 2010].  
4. The potential of regenerative medicine 
The term regenerative medicine refers to that field in the health sciences which aims to 
replace or regenerate human cells, tissues, or organs in order to restore or establish normal function 
[Mason & Dunnill, 2008; Orlando, Baptista et al., 2010; Orlando et al., 2011]. The process of 
regenerating body parts can occur in vivo or ex vivo and may require cells, natural or 
artificial scaffolding materials, growth factors, or different combinations of all three 
elements. Instead, the term tissue engineering refers to a field which is narrower in scope 
and strictly limited to the production of body parts ex vivo, by seeding cells either on or into 
a supporting scaffold [Orlando et al., 2011]. 
In the last decade, investigators in the field have been able to produce and implant in 
patients relatively simple hollow organs like skin [Naughton et al., 1999], vessels [Hibino et 
al., 2010; L’Heureux N et al., 2007; McAllister et al., 2009; Shinoka et al., 2001; Shinoka et al., 
2005;], bladders [Atala et al., 2006], windpipes [Macchiarini et al., 2008] and urethras [Raya-
Rivera et al., 2011]. Importantly, all constructs were manufactured by either combining 
autologous cells with scaffolding material, or through the engineering of autologous cells per 
se [Orlando, Baptista et al., 2010; Orlando et al., 2011]. Importantly, none of the patients did 
require IS at any time after implantation of the bioengineered body part. Therefore, 
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regenerative medicine has shown the potential to offer a valuable approach to COT. 
Importantly, as the above mentioned implanted body parts were bioengineered from 
autologous cells, recipients never required IS and therefore we can conclude that 
regenerative medicine offers the only possible approach to immediate, stable and durable 
COT. In fact, as illustrated throughout the whole chapter, all cases of COT reported so far in 
the English literature developed at least several weeks after the transplants and always 
required some IS, the exception being RT between identical twins [Orlando, Hematti et al., 
2010]. Moreover, in several circumstances, patients who could be weaned off IS eventually 
rejected and required resumption of IS. 
Bioengineering technology has been implemented to manufacture heart [Ott et al., 2008], 
liver [Badylak et al., 2011; Baptista et al., 2011; Uydun et al., 2010;] and lung [Ott et al., 2010; 
Petersen et al., 2010;] organoids from rodent organs [Orlando, Baptista et al, 2010; Orlando 
et al, 2011]. In extenso, rat or ferret organs were decellularized with detergents and 
repopulated with cells from unrelated species, humans included. In the ideal scenario, when 
and if this technology will be perfected, the cellular compartment will be reconstituted – 
even in this case – from patient’s autologous cells, whereas the supporting scaffold will be 
represented by an acellular porcine or non-human primate organ depleted of its native cells. 
5. Conclusions 
When all the above information is taken together, it is clear that, although a wealth of 
knowledge exists, little progress has been made in developing a sure-fire strategy towards 
attaining COT. Despite tolerance has been widely investigated for decades, efforts to 
understand the mechanisms underlying this phenomenon and how to achieve it have thus 
far been to no avail. In addition to the failure of all molecule-based strategies, we have 
learned that stem cells do exert some modulatory effect on the immune system but we do 
not know why and how this occurs. Therefore, we cannot predict when the opportunities 
for COT to develop in a patient the greatest.  
As it stands, with the technology that is currently available, the withdrawal of IS after RT 
cannot yet be encouraged because it is neither effective nor safe and must be considered as 
still in an experimental phase. Efforts to identify a peripheral blood transcriptional 
biomarker panel associated with COT after RT are certainly laudable but, provided the 
safety for the withdrawal of IS is not guaranteed, any clinical implementation should be 
banned outside specialized cutting-edge center. The lack of safety of all tolerogenic 
strategies implemented so far remains their major weakness. Recent revolutionary progress 
in regenerative medicine has revealed the immense potential of the field pertinent to COT. 
In a foreseeable future, regenerative medicine will meet the two major needs of SOT, namely 
that of a potentially inexhaustible source of organs and COT itself [Orlando, 2011]. 
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